ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AGIO Agios Pharmaceuticals Inc

33.22
-1.32 (-3.82%)
07 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Agios Pharmaceuticals Inc NASDAQ:AGIO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.32 -3.82% 33.22 32.87 34.92 35.11 33.21 34.76 684,342 01:00:00

Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020

27/08/2020 12:00pm

GlobeNewswire Inc.


Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Agios Pharmaceuticals Charts.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020 at 9:50 a.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

About AgiosAgios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at www.agios.com.

Contacts

Investors:Holly Manning, 617-844-6630Director, Investor RelationsHolly.Manning@agios.com

Media:Jessica Rennekamp, 857-209-3286Associate Director, Corporate CommunicationsJessica.Rennekamp@agios.com

1 Year Agios Pharmaceuticals Chart

1 Year Agios Pharmaceuticals Chart

1 Month Agios Pharmaceuticals Chart

1 Month Agios Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock